Renalytics to Present Real-World Evidence for KidneyIntelX Platform

October 17, 2022

Renalytics has announced that its speakers will give four presentations at this years American Society of Nephrology Kidney Week early this coming November. The talks will focus on the company’s real-world evidence (RWE) nephrology platform KidneyIntelX. One talk will elaborate on the platform’s use to determine kidney disease progression in Black Americans, while another will detail how the platform helped identify kidney health inequities

According to Yahoo Finance, “The KidneyIntelX risk score was assessed for its ability to predict progressive decline in kidney function in patients with T2D and early-stage CKD in a major healthcare system. Initial results suggest that despite similar median eGFR and median UACR levels, African American patients tested with KidneyIntelX were three times more likely to be scored as high risk. It is hoped that with continued use in the setting, KidneyIntelX may allow PCPs and healthcare systems to optimize the allocation of treatments and clinical resources to those at highest risk, beyond traditional clinical metrics and potentially improve equity in outcomes”

To read more, click here.

(Source: Yahoo Finance, October 17th, 2022)

Share This Story!